Date published: 2025-10-20

1-800-457-3801

SCBT Portrait Logo
Seach Input

Rosiglitazone (CAS 122320-73-4)

5.0(1)
Write a reviewAsk a question

See product citations (38)

Alternate Names:
Rosiglitazone is also known as BRL 49653.
Application:
Rosiglitazone is a potent and selective PPARγ agonist that exhibits anti-diabetic and hepatoxic effects.
CAS Number:
122320-73-4
Purity:
≥98%
Molecular Weight:
357.43
Molecular Formula:
C18H19N3O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Rosiglitazone is a potent, selective PPARgamma (Peroxisome proliferator-activated receptor) agonist (Kd= 43 nM). PPARgamma belongs to a group of nuclear receptor proteins that are essential to the regulation of cellular differentiation, development and metabolism, and plays a functional role in adipogenesis. Studies also suggest that PPARγ agonists can be anti-inflammatory agents. Rosiglitazone is a thiazolidinedione analog effective in inducing adipocyte differentiation in pluripotent C3H10T1/2 stem cells.


Rosiglitazone (CAS 122320-73-4) References

  1. Rosiglitazone.  |  Balfour, JA. and Plosker, GL. 1999. Drugs. 57: 921-30; discussion 931-2. PMID: 10400405
  2. A review of rosiglitazone in type 2 diabetes mellitus.  |  Werner, AL. and Travaglini, MT. 2001. Pharmacotherapy. 21: 1082-99. PMID: 11560198
  3. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.  |  Park, JY., et al. 2004. Clin Pharmacol Ther. 75: 157-62. PMID: 15001966
  4. Evidence for a potent antiinflammatory effect of rosiglitazone.  |  Mohanty, P., et al. 2004. J Clin Endocrinol Metab. 89: 2728-35. PMID: 15181049
  5. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.  |  , ., et al. 2006. Lancet. 368: 1096-105. PMID: 16997664
  6. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.  |  Rosen, CJ. 2007. N Engl J Med. 357: 844-6. PMID: 17687124
  7. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.  |  Ratziu, V., et al. 2010. Hepatology. 51: 445-53. PMID: 19877169
  8. Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.  |  Bocciardi, R. and Ravazzolo, R. 2010. PPAR Res. 2010: 541927. PMID: 20613955
  9. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells.  |  Yoon, SY., et al. 2010. Neurobiol Dis. 40: 449-55. PMID: 20655383
  10. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.  |  Setti, G., et al. 2010. Am J Nephrol. 32: 393-402. PMID: 20814199
  11. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).  |  Lehmann, JM., et al. 1995. J Biol Chem. 270: 12953-6. PMID: 7768881
  12. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.  |  Cantello, BC., et al. 1994. J Med Chem. 37: 3977-85. PMID: 7966158
  13. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.  |  Willson, TM., et al. 1996. J Med Chem. 39: 665-8. PMID: 8576907

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Rosiglitazone, 25 mg

sc-202795
25 mg
$118.00

Rosiglitazone, 100 mg

sc-202795A
100 mg
$320.00

Rosiglitazone, 500 mg

sc-202795C
500 mg
$622.00

Rosiglitazone, 1 g

sc-202795D
1 g
$928.00

Rosiglitazone, 5 g

sc-202795B
5 g
$1234.00

What is the appearance of the compound?

Asked by: two2igm05
Thank you for your question. Rosiglitazone, sc-202795, is a white to off-­white crystalline powder.
Answered by: Chemical Support 4
Date published: 2017-03-10
  • y_2025, m_10, d_14, h_6CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.42
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_202795, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getContent, 104ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from KarakasiliotiKarakasilioti, et. al. (PubMed ID 24011075) utilized SCBT product sc-202795 to activate PPAR in MMC-treated adipocytes; found that this had a marked abrogation of transcriptional induction of Il6, TNF and Kc mRNA levels. -SCBT Publication Review
Date published: 2015-04-20
  • y_2025, m_10, d_14, h_6
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.42
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202795, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getReviews, 8ms
  • REVIEWS, PRODUCT
Rosiglitazone is rated 5.0 out of 5 by 1.
  • y_2025, m_10, d_14, h_6
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.42
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202795, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getAggregateRating, 161ms
  • REVIEWS, PRODUCT